ArticleBMC ophthalmology2026
Comparison of visual performance outcomes following PanOptix and symfony ZXR00 intraocular lens implantation using the area under the distance-corrected defocus curve.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to compare visual performance, defined and quantified as the visual acuity reserve through the area under the distance-corrected defocus curve (AUC), along with visual acuity at discrete distances and modulation transfer function (MTF), following implantation of PanOptix TFNT00 trifocal and Symfony ZXR00 extended depth-of-focus intraocular lenses (IOLs).
methodsThis prospective study included patients, with only one eye per patient studied, who underwent cataract extraction with PanOptix or Symfony IOL implantation between May 2023 and May 2024 at Chongqing Aier Eye Hospital, China. Clinical data were collected at 3 months postoperatively. The total AUC (ST: 0.5D to -3.0D) and partial AUCs for distance (SD, + 0.5 to -0.5 D), intermediate (SI, -0.5 to -2.0 D), and near (SN, -2.0 to -3.0 D) ranges were calculated from distance-corrected defocus curves. Corrected visual acuity at discrete distance and MTF were also assessed.
resultsA total of 69 participants (69 eyes) were included, with 36 in the PanOptix group and 33 in the Symfony group. ST and SD did not differ significantly between groups. SI was greater in the Symfony group (P = 0.029), whereas SN was greater in the PanOptix group (P = 0.005). PanOptix achieved better near visual acuity (P < 0.001), while the best corrected distance visual acuity (BCDVA) and MTF values were similar. Postoperative refraction was more myopic in the Symfony group (P < 0.001).
conclusionsDefocus curve area analysis effectively delineated the distinct performance profiles of the two IOLs, with Symfony favoring intermediate and PanOptix favoring near vision.
trial registrationMR-50-25-076077, July 1, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.